CNTX
Context Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.36
−0.36%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$33.23M
MomentumView details →
1D Return
−0.36%
YTD Return
−75.77%
RSI (14)
27.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$33.23M
RSI (14)
27.9
MomentumView details →
1D Return
−0.36%
YTD Return
−75.77%
SummaryUpdated Jun 1, 2026
Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Philadelphia, Pennsylvania. The company went public in October 2021 and focuses exclusively on developing innovative cancer treatments specifically for women. Context Therapeutics operates as a pre-revenue biotechnology company, dedicating its resources to advancing two primary drug candidates through clinical trials targeting female hormone-dependent cancers and gynecologic malignancies.
Similar companies
Latest newsMore news →